• Novartis worked with US Food and Drug Administration (FDA) to update Beovu (brolucizumab) prescribing information to guide healthcare professionals in their treatment of wet AMD patients¹
   
• The update includes characterization of adverse events, retinal vasculitis and retinal vascular occlusion, as part of the spectrum of intraocular inflammation observed in the HAWK & HARRIER trials and noted in the original prescribing information¹
   
• Novartis has convened a fully dedicated team collaborating with …